/ /

Cataract & Refractive
Glaucoma monitoring implant receives ...

An implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, ...

Vitrectomy beats scleral buckling in ...
Researchers image single cell deaths ...
Posterior IOLs effective in keratoconus
Retina
Confocal scanner gives ...

Most ocular structures become luminescent for a short time when exposed to a light source of appropriate wavelength; this ...

Gene therapy trial launched for ...
Patients’ health jeopardized by ...
Global diabetes epidemic must not ...
Glaucoma
Glaucoma monitoring implant receives ...

An implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, ...

Researchers image single cell deaths ...
ECP provides primary secondary ...
Laser trabeculoplasty suitable for ...

Latest Issue

::after
::after

OTE Articles

12-month results with small-aperture IOL providing patients with an extended range of visionThe IC-8 IOL (AcuFocus) is one of the new class of extended-depth-of-focus (EDOF) IOLs that is definitively altering the landscape of cataract surgery in Europe and around the world. Whereas monofocal and multifocal lenses have one or two distinct focal points, an EDOF-IOL creates one elongated focal point, though each lens does so in a different way.
Gene therapy trial launched for X-linked retinitis pigmentosaResearchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP).
Defining dysfunctional lens syndromeRose is a rose is a rose is a rose--a line written (1913) by Gertrude Stein and its variations in a famous quotation are often interpreted as meaning “things are what they are--makes a statement of the law of identity, and in the post-factum age is ever more meaningful. An ophthalmologist could as well write: “Cataract is a cataract is a cataract is a cataract,” ICD-10 Code H25.0 for the diagnosis “Cataracta senilis incipiens” in its earliest stage and notably with a surgical history of more than 2,500 years.
Patients’ health jeopardized by failed ophthalmology follow-upFailure to follow-up after ophthalmology appointments can damage patients’ health, a new study suggests. “In our view, national consideration should be given to create targets for reporting how well providers are managing follow-up patients,” reported A Davis and colleagues in the journal Eye.
Aldehyde dehydrogenase implicated in mucous membrane pemphigoidPreliminary studies suggest disulfiram could aid in the treatment of mucous membrane pemphigoid (MMP). Used topically, the drug may inhibit aldehyde deydrogenase (ALDH), which plays a key role in fibrosis, wrote JK Dart, UCL Institute of Ophthalmology, London.
Evidence weak for blue light-filtering IOLsOnly weak evidence supports the use of IOLs that filter visible blue light, researchers say. “On the basis of currently available evidence, one cannot advocate for the use of blue-light-filtering IOLs over UV-only filtering IOLs,” wroite X. Li, Waterford Institute of Technology, Waterford, Ireland, and colleagues.
No sign of chloramphenicol resistance in bacterial conjunctivitisChloramphenicol remains effective against Gram-positive bacteria, the most common agent in bacterial conjunctivitis, researchers say.
Autoantibodies may serve as glaucoma biomarkersThe loss of autoantibodies may serve as useful biomarkers for glaucoma, according to Nadine von Thun Und Hohenstein-Blaul, Johannes Gutenberg University Mainz, Mainz, Germany, and colleagues.
Global diabetes epidemic must not become epidemic of blindnessThe global epidemic in type 2 diabetes mellitus is of unprecedented proportions. In absolute numbers, it probably exceeds any previous epidemic in the history of mankind. There are now more than 400 million people with diabetes in the world, and the number is projected to exceed 600 million by 2030.
Improving vision with electronic retinal implantsElectronic retina implants can restore enough vision for some patients to pursue tasks of daily living, according to RE MacLaren, part of a team testing the devices.